Do HMG-CoA reductase inhibitors improve kidney function? The saga continues

被引：9

作者：

Campese, Vito M. ^{[1
]}

Ku, Elaine ^{[1
]}

Bigazzi, Roberto ^{[1
]}

Bianchi, Stefano ^{[1
]}

机构：

[1] Univ So Calif, Keck Sch Med, Div Nephrol, Los Angeles, CA 90033 USA

来源：

JOURNAL OF NEPHROLOGY | 2011年 / 24卷 / 05期

关键词：

Chronic kidney disease; Proteinuria; Statins; C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; RENAL-FUNCTION; ROSUVASTATIN; ATORVASTATIN; PROGRESSION; DYSLIPIDEMIA; EFFICACY; STATINS; WOMEN;

D O I：

10.5301/jn.5000024

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Several reviews have addressed the role of dyslipidemia in renal injury and the potential renal protective effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). Experimental evidence in animals strongly supports the concept that statins may be renal protective. However, data in humans are scanty and contradictory. A recent controlled study using rosuvastatin has cast some doubts on the renal protective effect of this drug. This article reviews the available evidence pro and con the renal protective effects of statins in human subjects.

引用

页码：550 / 553

页数：4

共 15 条

[1] The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study [J].

Athyros, VG ;

Mikhailidis, DP ;

Papageorgiou, AA ;

Symeonidis, AN ;

Pehlivanidis, AN ;

Bouloukos, VI ;

Elisaf, M .

JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (07) :728-734

[2] A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease [J].

Bianchi, S ;

Bigazzi, R ;

Caiazza, A ;

Campese, VM .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (03) :565-570

[3] HMG-CoA reductase inhibitors and renal function [J].

Campese, Vito M. ;

Park, Jeanie .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 2 (06) :1100-1103

[4] Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia - Results from the ECLIPSE study [J].

Faergeman, Ole ;

Hill, Laurie ;

Windler, Eberhard ;

Wiklund, Olov ;

Asmar, Roland ;

Duffield, Emma ;

Sosef, Froukje .

CARDIOLOGY, 2008, 111 (04) :219-228

[5] Effect of lipid reduction on the progression of renal disease: A meta-analysis [J].

Fried, LF ;

Orchard, TJ ;

Kasiske, BL .

KIDNEY INTERNATIONAL, 2001, 59 (01) :260-269

[6]

KELLER D, 47 EUR REN ASS EUR D

[7] Rosuvastatin increases α-1 micrloglobulin urinary excretion in patients with primary dyslipidemia [J].

Kostapanos, Michael S. ;

Milionis, Haralampos J. ;

Gazi, Irene ;

Kostara, Christine ;

Bairaktari, Eleni T. ;

Elisaf, Moses .

JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (11) :1337-1343

[8] Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein [J].

Ridker, Paul M. ;

Danielson, Eleanor ;

Fonseca, Francisco A. H. ;

Genest, Jacques ;

Gotto, Antonio M., Jr. ;

Kastelein, John J. P. ;

Koenig, Wolfgang ;

Libby, Peter ;

Lorenzatti, Alberto J. ;

MacFadyen, Jean G. ;

Nordestgaard, Borge G. ;

Shepherd, James ;

Willerson, James T. ;

Glynn, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (21) :2195-2207

[9] Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein A Secondary Analysis From the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) Trial [J].

Ridker, Paul M. ;

MacFadyen, Jean ;

Cressman, Michael ;

Glynn, Robert J. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (12) :1266-1273

[10] Rosuvastatin: A review of its use in the management of dyslipidemia [J].

Scott L.J. ;

Curran M.P. ;

Figgitt D.P. .

American Journal of Cardiovascular Drugs, 2004, 4 (2) :117-138

← 1 2 →